Seizures Clinical Trial
Official title:
Comparison of 4 Weeks Versus 12 Weeks Anti-convulsant Therapy for Acute Symptomatic Seizure in Children With Acute Encephalitis Syndrome- Open Label, Randomized Controlled Trial
There are no guidelines or studies evaluating duration of anti-epileptic drugs in central nervous system infections. The duration of anti-epileptic drug is extrapolated from traumatic brain injury in which duration of 1 weeks to 3 months is suggested. So the investigators plan to conduct this study to decide the optimal duration of anti-epileptic drug in acute symptomatic seizure in central nervous system infections
Demography data, seizure details at diagnosis of acute encephalitis syndrome, details of
etiology, neuroimaging findings and electroencephalography. A detailed neurological
examination will be done in all participants and asked for seizure semiology at admission.
Seizure details include seizure type, duration, number of seizures, number of days for which
seizures were recurring, status epilepticus, encephalopathy in between seizures. After the
initial assessment participants would be randomized into 2 groups: Group 1: Anti-epileptic
drug for 4 weeks followed by taper in 10-14days and Group 2: Anti-epileptic drug for 12 weeks
followed by tapering over 10-14days. The primary outcome would be be to study the seizure
relapse rate (proportion) after stopping anti-epileptic drugs in participants with acute
symptomatic seizure given 4weeks and 12 weeks anti-epileptic drug therapy in the two study
groups.
Clinical status will be assessed at enrollment as defined by Pediatric Cerebral Performance
Category, Pediatric overall Performance Category and Glasgow Outcome Scale-Extended Pediatric
Version (GOS-P)
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02850913 -
Doxycycline for the Treatment of Nodding Syndrome
|
Phase 2 | |
Recruiting |
NCT04076449 -
Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy
|
||
Not yet recruiting |
NCT06045676 -
Electrocardiographic Changes Among Epileptic and Non Epileptic Seizures in Children at Sohag University Hospital
|
||
Completed |
NCT03722212 -
Early Diagnosis of the GLUT1 Deficiency Syndrome With a Blood Based Test
|
N/A | |
Not yet recruiting |
NCT05649891 -
Checklists Resuscitation Emergency Department
|
N/A | |
Completed |
NCT02897856 -
Efficacy and Safety of Intramuscular Midazolam Compared to Buccal Midazolam in Pediatric Seizures
|
Phase 4 | |
Completed |
NCT01236001 -
Belgian Drug-utilization Study to Evaluate the Use of VIMPAT® as Adjunctive Treatment of Partial Onset Seizures in Subjects Aged 16 and Older
|
N/A | |
Completed |
NCT01239212 -
Dosing of Levetiracetam (Keppra) in Neonates
|
Phase 1/Phase 2 | |
Completed |
NCT01703468 -
Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fed Conditions
|
Phase 1 | |
Completed |
NCT01702623 -
Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fasted Conditions
|
Phase 1 | |
Recruiting |
NCT02216500 -
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
|
N/A | |
Completed |
NCT00236717 -
A Study of the Effectiveness and Safety of Topiramate Compared With a Standard Therapy in Patients Newly Diagnosed With Epilepsy
|
Phase 3 | |
Terminated |
NCT03954314 -
DEPOSITION - Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery
|
Phase 3 | |
Completed |
NCT05103735 -
Propofol-remifentanyl Versus Dexmedetomidine in Awake Craniotomy: Impact on Electroclinical Seizure Activity
|
||
Terminated |
NCT03790436 -
Betaquik as an Adjunct to Dietary Management of Epilepsy in Adults on the Modified Atkins Diet
|
N/A | |
Completed |
NCT06451289 -
Study on Optic Nerve Sheath Diameter Measurements in Prolonged Pediatric Seizures
|
||
Recruiting |
NCT02552511 -
Epidemiology Study on Neonatal Seizure
|
||
Recruiting |
NCT05339126 -
RNS System LGS Feasibility Study
|
Phase 2 | |
Active, not recruiting |
NCT04595786 -
The Safety of Intravenous Tranexamic Acid in Patients Undergoing Supratentorial Meningiomas Resection
|
N/A | |
Recruiting |
NCT04770337 -
Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy
|
N/A |